Both marketed therapies are prescribed when a patient has shown an inadequate response to at least one conventional or biologic therapy.
Scope
- Alcohol consumption is one of the first focal points for changed behavior when consumers seek to pursue healthier lifestyles.
- Half of drinkers globally state they are often or always influenced in their product choice by how an alcoholic beverage impacts their health and wellbeing.
- More than two thirds of alcohol consumers find products that have been fortified with added nutrients to be somewhat or very appealing.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the CGT in Gastrointestinal market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact Gastrointestinal disease targeting CGT therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- TaTakeda Pharmaceutical
- Anterogen
- GlaxoSmithKline (GSK)
- AstraZeneca
- Alnylam Pharmaceuticals
- Mesoblast
- Shanghai Hexaell Biotech
- Pharmicell
- LyGenesis
- Resolution Therapeutics
- Avobis Bio
- DK-001

